Summit Therapeutics

Quarterly Financials

Values in thousands 2024-12-31 2024-09-30 2024-06-30 2024-03-31
Revenue
$0
$0
$0
$0
Gross Profit
-19
-20
-27
EBITDA
-61,145
-53,515
-57,422
-40,538
EBIT
-61,167
-53,535
-57,442
-40,565
Net Income
-61,203
-56,254
-60,385
-43,473
Net Change In Cash
0
0
0
0
Free Cash Flow
-48,687
-30,355
-32,912
-30,138
Cash
104,862
93,775
28,754
61,294
Basic Shares
722,598
726,656
707,904
701,785

Annual Financials

Values in thousands 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
$0
$0
$704
$1,809
Gross Profit
-15,007
-2,050
-1,809
1,809
EBITDA
313
1,001
-52,630
-83,731
EBIT
-89,736
-55,144
-86,186
Net Income
-221,315
-614,928
-74,381
-86,147
Net Change In Cash
0
0
704
1,809
Free Cash Flow
-142,245
-76,888
-42,206
-72,893
Cash
104,862
71,425
348,607
71,791
Basic Shares
718,541
619,646
193,336
92,239

Earnings Calls

Quarter EPS
2024-12-31
-$0.06
2024-09-30
-$0.08
2024-06-30
-$0.09
2024-03-31
-$0.06